Torl Biotherapeutics
Torl Biotherapeutics Raises $96M in Series C
Torl Biotherapeutics Raises $96M in Series C
Torl Biotherapeutics has successfully raised $96M in a Series C at a $500M valuation led by Cormorant Asset Management, BVF Partners.
Company Overview
Torl Biotherapeutics is a Biotech company headquartered in Los Angeles, CA, founded in 2019 with 90+ employees.
Antibody-based immunotherapies for cancer patients
Fundraising Details
- Amount Raised: $96M
- Round Type: Series C
- Valuation: $500M
- Date: 2025-10-10
- Investors: Cormorant Asset Management, BVF Partners
About Torl Biotherapeutics
Antibody-based immunotherapies for cancer patients The company is positioned in the Biotech sector, serving a growing market with innovative solutions.
Key Information
- Headquarters: Los Angeles, CA
- Founded: 2019
- Team Size: 90+
- Industry: Biotech
What This Means
This funding round demonstrates strong investor confidence in Torl Biotherapeutics's vision and execution. The capital will likely be used to:
- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities
Industry Context
The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Torl Biotherapeutics's successful fundraising reflects the strong fundamentals and growth potential in this space.
Valuation Milestone
Reaching a $500M valuation marks an important milestone for Torl Biotherapeutics, positioning the company among notable players in the Biotech industry.
Looking Ahead
With this new capital, Torl Biotherapeutics is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.
This fundraising news was reported on 2025-10-10. For more information about Torl Biotherapeutics, visit their headquarters at Los Angeles, CA.
Company Info
Share
Related Reports
Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform
Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.
Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation
French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.
AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment
Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free